How Signatera MRD testing is Transforming Cancer Care & Drug Development
Time: 8:50 am
day: Day Two AM
Details:
- The Signatera ctDNA MRD assay is shifting the paradigm of cancer management; ~40% of US oncologists ordered Signatera in Q1 2024 and to-date, over 175,000 real-world patients have been tested across 700,000+ longitudinal timepoints
- Increasingly, Signatera is being integrated into the physician-patient shared decision-making model across tumor types and practice settings
- Among 20+ studies prospectively using Signatera, several randomized Phase 3 trials are expected to report findings over the next 12 months, with potentially practice-changing implications
- This presentation will review the current state of the MRD field and areas where more effective therapies are needed for high-risk populations
